Human Peripheral Blood Macrophages, Frozen

Primary human cells, frozen
Human Peripheral Blood Macrophages, Frozen

Primary human cells, frozen

1.5 x 10^6 cells
  • Please select one of the preferences above when ordering multiple quantities

    Please indicate any specifications (e.g. sex, age range, BMI range, ethnicity, blood type, smoker status, CMV, HLA, etc.) in the comment box below. An additional surcharge will apply to requests for CMV, HLA, or other specifications requiring new donor recruitment. Please note that highly specific or multiple specifications may affect the delivery time.

Catalog # 70042
737 USD

Overview

Start with ready-to-use, ethically sourced, primary human macrophages. With personalized service, custom products, flexible delivery times, and the option to reserve entire lots to prescreen cells for applications, we help you get the cells you need.

Immunomagnetically selected peripheral blood monocytes are cultured in RPMI 1640 Medium (Catalog #36750) + 10% FBS, M-CSF, and IL-4 for 5 days to generate macrophages. Cells are collected using Institutional Review Board (IRB)-approved consent forms and protocols and cryopreserved in animal component-free CryoStor®CS10 medium (Catalog #07930). Additional documentation and high-resolution HLA typing (Class I and Class II alleles and CMV status) are available upon request. Acid-citrate-dextrose solution A (ACDA) is added during collection as an anticoagulant. Donor specifications (e.g. BMI category, smoking status, ethnicity, etc.) can be requested in the comment box above. Donors are screened for HIV-1, HIV-2, hepatitis B, and hepatitis C.

Certain products are only available in select territories. Please contact your local sales representative or Product & Scientific Support at techsupport@stemcell.com for further information.

Browse our Frequently Asked Questions (FAQs) on Primary Cells.
Contains
• CryoStor® CS10
Subtype
Frozen
Cell Type
Macrophages, Monocytes, Myeloid Cells
Species
Human
Cell and Tissue Source
Peripheral Blood
Donor Status
Normal
Purity
The purity of macrophages is ≥ 90% for MHC class II, CD11b, CD18, and CD68 by flow cytometry.

Scientific Resources

Product Documentation

Document Type Product Name Catalog # Lot # Language
Document Type
Product Information Sheet
Product Name
Human Peripheral Blood Macrophages, Frozen
Catalog #
70042
Lot #
All
Language
English

Educational Materials(3)

Brochure
Tools For Your Immunology Research
Brochure
Human Primary Cells
Video
6:05
How to Thaw Frozen Human Primary Cells

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Publications (2)

Cell host {\&} microbe 2020 TMEM173 Drives Lethal Coagulation in Sepsis. H. Zhang et al.

Abstract

The discovery of TMEM173/STING-dependent innate immunity has recently provided guidance for the prevention and management of inflammatory disorders. Here, we show that myeloid TMEM173 occupies an essential role in regulating coagulation in bacterial infections through a mechanism independent of type I interferon response. Mechanistically, TMEM173 binding to ITPR1 controls calcium release from the endoplasmic reticulum in macrophages and monocytes. The TMEM173-dependent increase in cytosolic calcium drives Gasdermin D (GSDMD) cleavage and activation, which triggers the release of F3, the key initiator of blood coagulation. Genetic or pharmacological inhibition of the TMEM173-GSDMD-F3 pathway blocks systemic coagulation and improves animal survival in three models of sepsis (cecal ligation and puncture or bacteremia with Escherichia coli or Streptococcus pneumoniae infection). The upregulation of the TMEM173 pathway correlates with the severity of disseminated intravascular coagulation and mortality in patients with sepsis. Thus, TMEM173 is a key regulator of blood clotting during lethal bacterial infections.
Molecular therapy : the journal of the American Society of Gene Therapy 2014 MAR Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells. Tareen SU et al.

Abstract

As sentinels of the immune system, dendritic cells (DCs) play an essential role in regulating cellular immune responses. One of the main challenges of developing DC-targeted therapies includes the delivery of antigen to DCs in order to promote the activation of antigen-specific effector CD8 T cells. With the goal of creating antigen-directed immunotherapeutics that can be safely administered directly to patients, Immune Design has developed a platform of novel integration-deficient lentiviral vectors that target and deliver antigen-encoding nucleic acids to human DCs. This platform, termed ID-VP02, utilizes a novel genetic variant of a Sindbis virus envelope glycoprotein with posttranslational carbohydrate modifications in combination with Vpx, a SIVmac viral accessory protein, to achieve efficient targeting and transduction of human DCs. In addition, ID-VP02 incorporates safety features in its design that include two redundant mechanisms to render ID-VP02 integration-deficient. Here, we describe the characteristics that allow ID-VP02 to specifically transduce human DCs, and the advances that ID-VP02 brings to conventional third-generation lentiviral vector design as well as demonstrate upstream production yields that will enable manufacturing feasibility studies to be conducted.
View All Publications

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.